Advertisement
Advertisement
PROK
ProKidney Corp. Class A Ordinary Shares
1.14
USDSponsored
+0.07
+7.04%
Nov 06, 15:40 UTC -5
Closed
After-Market
1.15
+0.01
+0.44%
ProKidney Corp. Class A Ordinary Shares (PROK) Earnings
PROK Earnings Reports
Positive Surprise Ratio
PROK beat 12 of 16 last estimates.
75%
Next Report
Today
Date of Next Report
Nov 09, 2026
Estimate for Q3 26 (Revenue/ EPS)
$127.09K
/-$0.14
Implied change from Q2 26 (Revenue/ EPS)
-15.27%
/-6.67%
Implied change from Q3 25 (Revenue/ EPS)
-41.43%
/+16.67%
ProKidney Corp. Class A Ordinary Shares earnings per share and revenue
On Aug 10, 2026, PROK reported earnings of -0.15 USD per share (EPS) for Q2 26, missing the estimate of -0.14 USD, resulting in a -4.53% surprise. Revenue reached 150.00 thousand, compared to an expected 151.98 thousand, with a -1.30% difference. The market reacted with a -4.73% price change (close before vs. close after earnings).
Looking ahead to Q3 26, -- analysts forecast an EPS of -0.14 USD, with revenue projected to reach 127.09 thousand USD, implying an decrease of -6.67% EPS, and decrease of -15.27% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Cronos Group Inc. Common Share
Report Date
Nov 05, 2026 For Q3 26
Estimate
$0.03
Actual
$0.04
Surprise
+17.65%
Aclaris Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.16
Actual
-$0.12
Surprise
+28.49%
Protara Therapeutics, Inc. Common Stock
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.37
Actual
-$0.35
Surprise
+6.17%
Minerva Neurosciences, Inc
Report Date
Nov 06, 2026 For Q3 26
Estimate
-$0.12
Actual
$1.94
Surprise
+1,629.97%
Organogenesis Holdings Inc. Class A Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.17
Actual
-$0.25
Surprise
-40.06%
ZOETIS INC.
Report Date
Nov 05, 2026 For Q3 26
Estimate
$1.52
Actual
$1.75
Surprise
+14.64%
Dyne Therapeutics, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.92
Actual
-$1.06
Surprise
-15.57%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.38
Actual
-$0.38
Surprise
+1.04%
Aldeyra Therapeutics, Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.09
Actual
-$0.06
Surprise
+37.43%
Lipocine Inc.
Report Date
Nov 05, 2026 For Q3 26
Estimate
-$0.36
Actual
-$0.08
Surprise
+77.91%
FAQ
What were ProKidney Corp. Class A Ordinary Shares's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, ProKidney Corp. Class A Ordinary Shares reported EPS of -$0.15, missing estimates by -4.53%, and revenue of $150.00K, -1.3% below expectations.
How did the market react to ProKidney Corp. Class A Ordinary Shares's Q2 2026 earnings?
The stock price moved down -4.73%, changed from $1.69 before the earnings release to $1.61 the day after.
When is ProKidney Corp. Class A Ordinary Shares expected to report next?
The next earning report is scheduled for Nov 09, 2026.
What are the forecasts for ProKidney Corp. Class A Ordinary Shares's next earnings report?
Based on --
analysts, ProKidney Corp. Class A Ordinary Shares is expected to report EPS of -$0.14 and revenue of $127.09K for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.